Prices of Capmatinib and Savotinib

Capmatinib (Capmatinib) and Savolitinib (Savolitinib) are drugs that belong to the tyrosine kinase inhibitor (TKI) class and are used to treat specific subgroups of patients with non-small cell lung cancer (NSCLC). The main target of capmatinib is MET kinase, especially in NSCLC patients with MET exon 14 skipping mutations. The main target of saivotinib is also MET kinase, and it is mainly used to treat NSCLC patients with MET exon 14 skipping mutations. Similar to capmatinib, saivotinib interferes with the growth and spread of cancer cells by inhibiting the activity of MET kinase.

The original drug of capmatinib is not on the market in China. The original drug currently sold in Hong Kong is 200mg*60 tablets. The price of each box may be more than 30,000 yuan. The actual price paid may be adjusted due to exchange rate changes. The European version of the original drug sold overseas, with a specification of 200mg*120 tablets, may cost more than 50,000 yuan per box, which is also affected by the exchange rate. Generic drugs are also sold overseas, and their ingredients are basically the same as the original drugs. For the original drugs produced by Laos pharmaceutical factories with a specification of 200mg*60 tablets, the price of each box may be more than 3,000 yuan, which is also affected by the exchange rate.

Savotinib is currently on the market in China and is included in Class B medical insurance, but it is only reimbursed for eligible patients, that is, adult patients with locally advanced or metastatic NSCLC whose disease has progressed after platinum-containing chemotherapy or who are intolerant to standard platinum-containing chemotherapy, or who have MET exon 14 skipping. The common specifications in China may be 200mg*21 tablets, and the price of each box may be more than 6,000 yuan. The price may be reduced after medical insurance reimbursement. Savotinib is currently not sold overseas.